Clinical Report: FDA Approves At-Home Starting Dose for Lecanemab
Overview
The FDA has approved a new subcutaneous starting regimen for lecanemab-irmb, allowing patients with Alzheimer's disease to begin treatment at home. This marks the first time patients can initiate treatment for Alzheimer's disease at home.
Background
Alzheimer's disease affects over 6.5 million Americans and is characterized by amyloid beta plaques and tau tangles leading to neuronal loss. The approval of lecanemab-irmb for at-home initiation represents a change in how treatment can be started.
Data Highlights
The approval was supported by data from two large randomized, placebo-controlled clinical trials evaluating intravenous lecanemab-irmb.
Key Findings
Lecanemab-irmb is an amyloid beta-directed antibody indicated for Alzheimer's disease treatment.
The subcutaneous formulation allows for at-home administration.
The intravenous formulation showed efficacy in reducing amyloid plaques and improving cognitive outcomes.
Patients homozygous for the apolipoprotein E ε4 allele are at higher risk for amyloid-related imaging abnormalities (ARIA).
Common adverse reactions include headache, infusion-related reactions, and ARIA.
Injection-site reactions are associated with the subcutaneous formulation.
Clinical Implications
Monitoring for ARIA and understanding the risks associated with apolipoprotein E ε4 status is crucial.
Conclusion
The FDA's approval of the at-home starting dose for lecanemab-irmb enhances patient access to therapy.
This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.
In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.
